Search
for
Sort by
Research 391–420 of 1000+
- The Dermatological Spectrum of Coronavirus Disease-19 Disease: Cutaneous Signs for Diagnostics and Prognosis and an Expanded Classification
- Botulinum Toxins in Medical and Cosmetic Dermatology
- Two cases in which tofacitinib effectively treated both ulcerative colitis and alopecia areata
- The JAK/STAT signaling pathway: from bench to clinic
- TRP Channels in Skin Biology and Pathophysiology
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
- Cutaneous Neuroimmune Interactions in Peripheral Neuropathic Pain States
- The Role of Sex and Gender in Dermatology - From Pathogenesis to Clinical Implications
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Utilities of Botulinum Toxins in Dermatology and Cosmetology
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- Anifrolumab treatment improves patient-reported quality of life and decreases disease activity and corticosteroid use in patients with systemic lupus erythematosus: A qualitative study in Denmark
- Alopecia Areata
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Subject Index
- Medicinal and cosmetic products used in treatment of hair loss
- Cutaneous and Mucosal Lichen Planus: A Comprehensive Review of Clinical Subtypes, Risk Factors, Diagnosis, and Prognosis
- RASopathic Skin Eruptions during Vemurafenib Therapy
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Psychological interventions in the management of common skin conditions
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- Scalp Pruritus: Review of the Pathogenesis, Diagnosis, and Management
- Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
- Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study